BIOA Stock Analysis: Buy, Sell, or Hold?
BIOA - BioAge Labs, Inc. Common Stock
$22.78
0.46 (2.06%)
▲
5d:
+11.18%
30d:
+37.15%
90d:
+41.4%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When BIOA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: BIOA is 14.4% above its trading range ($19.91). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: BIOA is 14.4% above its trading range ($19.91). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: BIOA is currently trading at $22.78, which is considered extended relative to its 30-day fair value range of $15.48 to $19.91.
Technical Outlook: Technically, BIOA is in a downtrend. The price is approaching resistance at $23.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIOA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.50 (+121.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BIOA is in a downtrend. The price is approaching resistance at $23.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIOA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.50 (+121.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.48 -
$19.91
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+14.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 121.8% below Wall St target ($49.50)
Trading Range Analysis
30-Day Trading Range
$15.48 -
$19.91
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$15.14
Resistance Level
$23.14
Current Trend
Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.83
Wall Street Target
$49.50
(+121.8%)
Revenue Growth (YoY)
91.0%
Share & Embed Analysis
Last updated: June 24, 2026 2:28 PM ET
Data refreshes hourly during market hours. Next update: 3:28 PM
Data refreshes hourly during market hours. Next update: 3:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIOA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Paul D Rubin
SELL
7433 shares
2026-02-02
Dov A Md Goldstein
SELL
27000 shares
2026-01-13
Kristen Fortney
SELL
233107 shares
2026-01-13
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
